28541 – THE EFFICACY OF CARBOPLATIN IN NEOADJUVANT TREATMENT OF TRIPLE-NEGATIVE BREAST CARCINOMA IN PATIENTS TREATED AT HOSPITAL GERAL DE CAXIAS DO SUL

Resumo

Introduction: In Brazil, breast cancer is the most common neoplasm among women and also the leading cause of cancer-
-related death. Approximately 20% of patients have triple-negative breast cancer (TNBC), for which chemotherapy remains
the main neoadjuvant treatment. Patients who achieve a pathological complete response (pCR) after chemotherapy have
demonstrated better survival outcomes. Conclusion: Our sample had a pCR rate of 57.1%, making it a financially feasible treatment within the Unified Health System (SUS). We observed good treatment tolerance. The median follow-up was
17 months, with 20% of patients deceased.